For example, a recent study identified that alterations in STK11/LKB1 and/or KEAP1 enhance the antitumor activity of ATR inhibitors in non-small cell lung cancer in vitro and in vivo [164]. Here, STK11 is linked to non-small cell lung carcinoma.